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Abstract
Drug-drug interaction is one of the important problems of Adverse Drug Reaction (ADR).
In this paper we develop an optimization approach for the study of this problem. This approach
is based on drug-reaction relationships represented in the form of a vector of weights, which
can be defined as a solution to some global optimization problem. Although this approach can
be used for solving many ADR problems, we concentrate here only on drug-drug interactions.
Based on drug-reaction relationships, we formulate this problem as an optimization problem.
The approach is applied to different classes of reactions from the Australian Adverse Drug
Reaction Advisory Committee (ADRAC) database.
Keywords: global optimization; adverse drug reaction; multi-label classification; drug-drug inter-
action
1 Introduction
An Adverse Drug Reaction (ADR) is defined by WHO as: “a response to a drug that is noxious
and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy
of disease, or for modification of physiological function” [20]. ADRs are estimated to be the fourth
leading cause of death in the USA [14], and the amount of published literature on the subject is
vast [1]. Some of the problems concerning ADRs are discussed in our research report [7]. Many
approaches have been tried for the analysis of adverse reaction data, such as: Fisher’s Exact Test
and matched pair designs (McNemar’s test) [18], Reporting Odds Ratio (ROR). One approach that
has had some success is the Proportional Reporting Ratios (PRR) for generating signals from data
in the United Kingdom. The Norwood-Sampson Model has been applied to data in the United
States of America and approved by the Food and Drug Administration. A common approach
to the assessment of ADRs uses the Bayesian method [4]. For example, the Bayesian confidence
propagation neural network (BCPNN) [2], an empirical Bayesian statistical data mining program,
called a Gamma Poisson Shrinker (GPS) [5], and the Multi-item Gamma Poisson Shrinker (MGPS)
[16], which have been applied to the United Sates Food and Drug Administration Spontaneous
Reporting System database.
Each method has its own advantages and disadvantages with respect to applicability in different
situations and possibilities for implementation. In [7], [10], [11] a new approach was developed
where the main goal was to study, for each drug, the possible reactions that can occur; that is,
to establish drug-reaction relationships. In these studies the ADR problem was formulated as
a text categorization problem and the drug-reaction relationships defined as a solution to some
global optimization problem. This approach was applied to the Australian Adverse Drug Reaction
Advisory Committee (ADRAC) database.
The approach developed in [7], [10], [11] allows us to study many ADR problems. In this paper
we mainly concentrate on drug-drug interactions. We discuss the possibility of using this approach
to the study of drug-drug interactions. The numerical experiments have been carried out on the
basis of different classes of reactions in ADRAC database.
1
2 ADRAC database
The ADRAC database has been developed and maintained by the Therapeutic Goods Adminis-
tration (TGA) with the aim to detect signals from adverse drug reactions as early as possible. It
contains 137,297 records collected from 1972 to 2001. In the initial preprocessing stage we remove
the records with missing information in fields related to reactions and drugs, and, further we con-
sider 137,172 records having a complete information in these fields. A more detailed account of
the ADRAC database is given in [7].
To define reaction classes, we will use a reaction tree presented in ADRAC database. This tree
contains two levels. The first level, that will be referred to as All Data, consists of 18 different
type of reaction classes called System Organ Class (SOC). Four of these classes contain subclasses
of reactions that defines the second level. These classes are: Blood, Body, Cardiovascular and
Neurological. To generate datasets related to these four reaction classes we collect all records having
at least one reaction from these four classes. The Cardiovascular class contains four subclasses and
Blood, Body and Neurological classes contain three subclasses.
In fact, records may have reactions from different classes. We need to take into account this
situation when generating datasets corresponding to each of these four classes. Thus, we define
one extra subclass, for each class, that contains reactions belonging to the other 17 SOCs. For the
number of records in each subclass see Table 2 presented in Section 3.
The information about each patient consists of mainly two sets of information: individual
patient information and information about drug(s) and reaction(s). In this paper we will use only
the second set of information. By understanding the drug-reaction relationship in the absence of
information about other factors influencing this relationship, we expect to be able to establish a
clearer relationship between drugs and reactions. Another reason for focussing primarily on drugs
and reactions relates to the inconsistent quality and quantity of relevant data on factors which
also play a role in the drug-reaction association. This is largely due to the voluntary nature of
the ADRAC reporting system. Some of the problems of such a reporting system are discussed in
([3],[6], [13], [17], [19]).
Therefore, we consider drug-reaction relationships not involving any other patient information.
In other words we define for each drug a vector of weights which indicate the probability of
occurrence of each reaction. This problem can be considered as a text categorization problem,
where each patient is considered as one document, and the set of drug(s) taken by this patient is
considered as a text related to this document; that is, each drug is considered as a word. For a
review of some of the issues in text categorization see [15], [21], [22].
2.1 Drug-reaction representations
We denote by X the set of all patients and by D the set of all drugs used by these patients. Let
c be a finite number of possible reaction classes. As mentioned above, we will consider two level
reaction classes. In the first level (that is, for All Data), we have c = 18; in the second level we
have c = 5 for Cardiovascular class and c = 4 for Blood, Body and Neurological class of reactions.
Given drug d ∈ D drug-reaction relationships will be represented by a vector
h(d) = (h1(d), h2(d), . . . , hc(d)),
where non-negative numbers hi(d) stand the weights (“probabilities”) of the occurrence of the
reactions i = 1, 2, . . . , c. The goal of the study of drug-reaction relationships is to find these
relationships, that is, the function h : D → Rc+, in an optimal way. Here Rc+ is the set of all
c-dimensional vectors with non-negative coordinates.
Given a set of drugs ∆ ⊂ D, we define a vector
H(∆) = (H1(∆), H2(∆), . . . ,Hc(∆)), Hi(∆) =
∑
d∈∆
hi(d), i = 1, . . . , c; (2.1)
where the component Hi(∆) indicates the probability of occurrence of the reaction i after taking
the drugs ∆. We call H(∆) a vector of Potential Reactions related to the set ∆ (see [7]).
2
3 Drug-drug Interactions
Drug-drug Interaction is one of the main problems of ADR. The proposed approach of drug-reaction
presentations allows us to consider this problem from a mathematical point of view.
There is not an explicitly formulated and commonly used definition for this problem. For future
discussions, we will use a definition presented in [12], where the drug-drug interaction problem is
described as follows:
Definition 3.1 ([12]) “A drug-drug interaction occurs when the effect of one drug is altered by
the presence of another drug in the Body. For example:
D1. One drug might reduce or increase the effects of another drug.
D2. Two drugs taken together may produce a new and dangerous interaction.
D3. Two similar drugs taken together may produce an effect that is greater than would be
expected from taking just one drug.”
In this definition, two different effects from drugs are considered: - the effect of drugs in terms
of recovery from some diseases, and, - the effect of drugs in terms of producing some aside reactions
(ADRs). For the sake of definiteness, we have to consider these effects separately.
One aspect of Definition 3.1 is related to recovery from taking the drugs. The main conclusion
we can make from this definition is that:
(a) the effects are directed to increase or decrease of some features (functions) in the Body;
and,
(b) for the normal recovery, these effects should be at some optimal levels.
Then, it is clear that, normal recovery will be impossible if the level of these effects is greater or
less than the optimal level, and, this will produce situations (in particular, adverse drug reactions)
described in Definition 3.1. Such situations may occur using only one drug (for example, in
Cardiovascular class there are 3 records, having just one drug used, reported as drug interaction).
We note that the introduction of vectors h(d) has been inspired by a (data mining) approach
where the goal was to describe the possible side reactions that can occur after taking the drug
d. This requires an assumption that, all the components of these vectors are non-negative, and,
a large number in these components show a high probability of the corresponding reactions. In
particular, this large number can be considered as a large deviation (divergency) from the optimal
levels described in (b).
The study of the effects of drugs in terms of recovery requires considering quite different kinds
of drug-reaction relationships describing the influence of drugs on some functions (features). In
this case, negative numbers could be used to describe the effects directed to the decrease of these
features. The study of this kind of drug-reaction relationships will be very important, although
this probably will require explicit description of drugs and more medical investigations.
In this paper, we consider drug-reaction relationships in the form of vectors h(d) defined in
Section 2.1. Now we discuss how this approach matches with Definition 3.1 in terms of side
reactions; in other words, we aim to discuss how drug-reaction presentations, in the form of vector
of weights, could be used for description of drug-drug interactions.
Consider, for example, two drugs d1, d2, with weights h(d1), h(d2) ∈ Rc+, and assume that
H(x) = h(d1) + h(d2) is a vector of potential reactions. Clearly, H(x) ≥ h(di), (i = 1, 2). This
means that, the effect from two drugs taken together will be stronger than the effect expected from
taking just one drug. In other words, potential reactions, defined above, can be used to study part
D1 (except for the part related to reduction of effect) and part D3 of Definition 3.1. The more
interesting case is D2. We now consider this case in detail.
3.1 Case D2
The reality is that, one drug causes not one but many different reactions. The grouping of similar
reactions under one class (using by a reaction tree) also does not help: almost every drug causes
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many different types of reaction classes. This requires that we consider the following cases sepa-
rately:
D2.1. Two (or more) drugs taken together may produce a new type of reaction(s) that has
not been observed with these drugs when they used alone.
D2.2. Two (or more) drugs taken together mainly produce a new type of reaction(s) that is
different from the reaction(s) mainly observed with these drugs when they used alone.
The second case, D2.2, can be well explained by drug-reaction relationships in the form of
vectors h(d). Consider an example. Let there be 5 reaction classes and
h(d1) = (0.6, 0.4, 0.0, 0.0, 0.0), h(d2) = (0.0, 0.4, 0.6, 0.0, 0.0).
The vector of potential reactions related to these two drugs is
H = (0.6, 0.8, 0.6, 0.0, 0.0).
This means that the first and the third reactions mainly occurred when the drugs were used alone,
but when they used together, the second reaction becomes the main reaction.
The interesting case is D2.1 which coincides with D2 of Definition 3.1. This case arises if, say
for the example above, the fourth reaction occurs for some patient after taking the two drugs. This
is the case, that cannot be studied by the approach of drug-reaction relationships h(d). We note
two important issues related to this case.
Note 1: Drug Combinations
How to study the case D2.1? To be able to study this case, we have to consider each combina-
tion of drugs in interaction separately. Moreover, we need to have enough records with the same
combination of drugs, in order, to derive statistically significant results.
Table 1: The repeating combinations of drugs in interaction. Ncomb is the number of different
combinations; Nfreq is the number of frequency of each combination
All Data Ncomb 1 1 2 2 3 5 7 29 102
Nfreq 28 19 10 9 6 5 4 3 2
Blood Ncomb 1 1 1 1 2 7 9 42
Nfreq 22 18 9 8 5 4 3 2
Body Ncomb 1 1 1 2 15
Nfreq 10 7 4 3 2
Neurological Ncomb 1 1 9 31
Nfreq 8 5 3 2
Cardiovascular Ncomb 1 4 16
Nfreq 9 3 2
The calculation of the number of repeating combinations and their frequencies provided the
results presented in Table 1. From this table we see that only a few number of combinations
repeated “many” times. For example, in the Cardiovascular type of reactions, there are 364
drug-drug interaction cases, where each record uses 2 to 7 drugs under interaction. The counting
of repeating combinations provided the following results: one combination occurred 9 times, 4
different combinations occurred 3 times and 16 different combinations occurred only 2 times.
Moreover, it is most likely that, the majority of each of these repeating cases related to one
person having multiple records in the data. All the other records use different combinations of
drugs in interactions! Similar situations we observe for the other classes and also for All Data
(that is, 18 SOC). For example, in All Data there are only 6 different combinations of drugs that
occurred more than 9 times and the records corresponding to these repeating cases is less than 4.5
percent of all drug-drug interaction cases. Therefore, the approach of considering different drug
combinations cannot be effective in the study of drug-drug interactions in general.
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To have “enough” repeating combinations, we have to use drug classes (generated from similar
drugs) instead of drugs (defined by trade names in this paper). Therefore, the case D2.1 needs
substantial investigations including generating drug classes.
Note 2: The frequency of records classified as D2.1
Now we consider the problem how frequently the case D2.1 occurs. In other words, we want to
know, how many records, out of all drug-drug interactions, can be classified as a case D2.1. This
is an interesting question. It turns out that even to count the number of these records is not easy.
The difficulty is related to defining the statement that “a drug is used alone”. We consider here
three different definitions:
• drug d is the only drug that has been taken (in this case, of course, it is also a suspected
drug);
• drug d is the only drug reported as a suspected drug out of all the drugs (more than two)
that have been taken; and
• drug d is one of the drugs (more than two) reported as suspected drugs (but not interacted).
Clearly, the last definition leads to a large number of reaction classes associated to this drug when
it is used alone. The fact is that we cannot ignore this definition, as it states that, this drug was a
suspected drug (the presence of other suspected drugs does not provide any additional information)
in reactions observed.
Therefore, considering these three definitions, we aim to count the number of records that can
be classified as D2.1. For this, we first generate three sets of records, having no drug interactions,
named Data1, Data2 and Data3. Data1 combines all the records having only one drug used,
Data2 combines all the records having only one drug reported as suspected, and Data3 combines
all records (having of course, no drug interactions). Then, we define that, a record, having an
interaction of drugs di , ..., dm, belongs to the case D2.1, if some reaction, observed for this
record, is not observed for all these drugs in the corresponding data (Data1, Data2 or Data3). The
results obtained are presented in Table 2.
Table 2: The number of records classified as D2.1 corresponding to data Data1, Data2 and
Data3: n1 corresponds to Data1, n2 corresponds to Data2, n3 corresponds to Data3. c is the
number of classes/subclasses, N is the total number of records in each class of reactions, Ninter is
the number of records having drug-drug interactions
Reaction tree c N Ninter n1 n2 n3
All Data 18 137172 1668 28 15 6
Blood 4 8574 460 7 1 0
Body 4 34456 420 6 4 1
Cardiovascular 5 21871 364 7 4 1
Neurological 4 50591 683 6 3 1
As we can see from Table 2 the total number of drug-drug interactions in the ADRAC database
is 1668 out of 137172 records. In this table we also present the number of drug-drug interactions in
each of four classes of reactions. We note that some drug-drug interactions, having reactions from
different classes, are present in different classes of reactions; that is, there is overlapping between
these four classes.
The main conclusion that we can draw from Table 2, is that the number of drug-drug inter-
actions classified as D2.1 is sufficiently small. For example, in the class of Blood there are 7
records according to Data1, only 1 record according to Data2 and none record according to Data3.
Even, considering all ADRAC data, that is, 1668 drug-drug interaction cases, we have 28 records
according to Data1, 15 records according to Data2 and only 6 records according to Data3.
Thus, there are only a few records corresponding to the case D2.1. Moreover, the analysis of
these records shows that, it is quite possible, these numbers could be much smaller, if the drugs
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in interactions were indicated more “correctly”. To explain this, consider the record from the year
1987 (we call it Record(1987)), which used 4 drugs: ID numbers 460, 782, 3498, 4714. This record
is classified as D2.1 according to Data3 in both Cardiovascular class and All Data. First consider
this record in Cardiovascular class that consists of 5 subclasses. The vector of observed reactions
is (1, 0, 0, 0, 1), which means that the first and fifth (that is, others) reactions have been observed.
The frequency of reactions related to these drugs are presented in Table 3.
Table 3: The frequency of reactions related to the drugs with ID numbers 460, 782, 3498, 4714,
corresponding to data Data3. Fk stands for the frequency of k-th reaction subclass in the Cardio-
vascular class (k = 1, ..., 5). (i) indicates the drugs in interaction, “+” in row R stands for the
reactions observed in the patient Record(1987) who took these four drugs
R + +
Drug ID F1 F2 F3 F4 F5
460 (i) 0 0 0 0 0
4714 (i) 0 0 2 1 0
782 35 8 33 48 117
3498 50 5 21 17 83
For this record, it was reported that the drugs 460 and 4714 had interacted. As we can see,
drugs 460 and 4714 are not associated with the observed reactions (the first and the fifth), as a
result, this case is considered as D2.1. In this case, the identification of drugs 782 and 3498 as
non-suspected might be an error (or misprint), because these drugs frequently caused the first and
the fifth reactions. If, it was an error, then the record Record(1987) would not be classified as
D2.1.
The same situation for this record, is found while considering all the 18 SOC; that is, All Data
(see Table 4). In this case this record was classified as D2.1 because of the occurrence of the
second class of reactions that was not observed with the drugs 460 and 4714 when they used alone
according to data Data3. The conclusion that these drugs interacted might be an error as the other
drugs, 782 and 3498, have a high frequency of causing this class of reactions when used alone.
Table 4: The frequency of reactions related to the drugs with ID numbers 460, 782, 3498, 4714,
corresponding to data Data3. Fk stands for the frequency of k-th reaction class in All Data (k =
1, ..., 18). (i) indicates the drugs in interaction, “+” in row R stands for the reactions observed
in the patient Record(1987) who took these four drugs
R + + + + + + +
Drug ID F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18
460 (i) 6 3 2 2 2 1 1 1 1 1
4714 (i) 1 1 3 1 2 1 3 1 2
782 149 39 6 205 114 66 24 30 13 105 68 25 19 26 2 2 131
3498 54 3 4 111 16 40 21 13 3 68 18 22 11 1 87
Therefore, according to Notes 1 and 2, we will only concentrate on the case D2.2, which, as
mentioned above, can be well described by our approach.
We also mention one very important issue. The records with interaction can be divided into
two parts: the first part that combines all records where all the drugs taken are reported as
interacting, and the second part that only some drugs, out of all drugs taken, are reported as
interacting. To evaluate the accuracy for the first part of the records is quite difficult. This needs
to develop new methods for evaluation. The method described in Section 5 can be used for the
second part of interactions. We will consider only this part aiming to check the possibility of using
drug-reaction relationships for the study of drug-drug interactions. Good results obtained in this
way will indicate the reasonableness and efficiency of the proposed approach.
Therefore, in this paper, we aim to study the possibility of using vectors of weights h(d),
calculated for each drug, for drug-drug interactions. In other words, we aim to check the closeness
of potential reactions to the observed reactions for patients having interactions of drugs. In this way,
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we can establish the accuracy with which the potential reactions could be used for the prediction
of reactions in drug-drug interaction cases.
4 An optimization approach to determine drug-reaction rep-
resentations
In this section we describe the Algorithm A(p), that uses an optimization approach to determine
drug-reaction representations.
Given a vector V = (V1, · · · , Vc), with nonnegative coordinates, we will use the notation
‖V ‖ =
c∑
i=1
Vi. (4.2)
Let x ∈ X . We denote by Y(x) = (Y1(x),Y2(x), · · · ,Yc(x)) a c-dimensional vector of reactions
observed for this patient; where Yi(x) = 1 if the reaction i has occurred, and Yi(x) = 0 if it has
not. Let D(x) be the set of all drugs taken by the patient x and H(x) = H(D(x)) is a vector of
potential reactions (see (2.1)).
We define the distance between predicted potential reactions H(x) = (H1(x), . . . ,Hc(x)) and
observed reactions Y(x) = (Y1(x), . . . ,Yc(x)) as:
dist (H(x),Y(x)) =
c∑
i=1
(H¯i(x)− Yi(x))2; (4.3)
where the sign “bar” stands for a normalization with respect to the number of observed reactions
‖Y(x)‖ :
H¯i(x) =
{
‖Y(x)‖
‖H(x)‖ Hi(x) if ‖H(x)‖ > 0;
0 if ‖H(x)‖ = 0. (4.4)
Given p = 0, 1, 2, we will use the following distance measure (we assume that ‖Y(x)‖ > 0):
distp (H(x),Y(x)) = ‖Y(x)‖−p · dist (H(x),Y(x)), p = 0, 1, 2. (4.5)
Note that, these distance functions are slightly different from the Linear Least Squares Fit (LLSF)
mapping function used in text categorization (see, for example, [21], [22]).
The algorithm A(p) aims to define drug-reaction relations h(d) minimizing the average dis-
tance distp (H(x),Y(x)) over all training examples. In other words, we consider the following
optimization problem:
Epav =
1
|X |
∑
x∈X
distp (H(x),Y(x)) → min; (4.6)
subject to : hi(d) ≥ 0, i = 1, ..., c, d ∈ D. (4.7)
Here |X | stands for the cardinality of the set X .Note that by taking different numbers p = 0, 1, 2,
we get different versions of A(p), p = 0, 1, 2, which generate different drug-reaction representations
h(d).
Therefore drug-reaction representations will be defined as a solution to the optimization prob-
lem (4.6)-(4.7). The function in (4.6) is non-convex and has a large number of local minimum
points. The number of variables is |D| · c. For the All Data, we have |D| = 5057 and c = 18. Thus
we have a global optimization problem with extremely large number of variables, which is very
hard to handle using existing global optimization methods. Taking into account some peculiarities
of the problem, we suggest an algorithm which allows us to find sufficiently “deep” local minimum
point of the objective function in (4.6). We solve this problem in three steps.
Step 1. First we find some “good” initial point for the problem (4.6), (4.7). In this stage we
use a method developed in [11]. Let this initial point be
h0(d) = (h01(d), ..., h
0
1(d)), d ∈ D. (4.8)
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Step 2. In the second step, we introduce new variables λ(d), d ∈ D, and represent (scale) drug
reaction relationships in the form:
h(d) = λ(d) (h01(d), ..., h
0
1(d)), d ∈ D. (4.9)
Then we consider the global optimization problem
1
|X |
∑
x∈X
distp (H(x : λ),Y(x)) → min; (4.10)
subject to : 0 ≤ λ(d) ≤ 2, d ∈ D; (4.11)
where H(x : λ) = (H1(x : λ), ...,Hc(x : λ)) and
Hi(x : λ) =
∑
d∈∆(x)
λ(d)h0i (d).
The number of variables in this problem is equal to the number of drugs. The use of formula
(4.9) means that we take as stable the proportions between weights, for each drug, calculated in
the first step. For the patients having only one drug (this is, about 50 percent of all records), the
scaling (4.9) does not affect the classification. The effect of this scaling works when two or more
drugs were involved together. The large numbers λ(d) obtained as a solution to (4.10), (4.11) will
indicate the importance of these drugs in terms of causing reactions.
To solve this problem we apply the algorithm AGOP which is developed in [8], [9]. Let the
optimal solution to the problem (4.10), (4.11) be λ0(d), d ∈ D, which provides the weight
vectors
h1(d) = (h11(d), ..., h
1
c(d)), h
1
i (d) = λ
0(d)h0i (d), d ∈ D, i = 1, ..., c. (4.12)
Step 3. In the last step, we consider the problem
Epav =
1
|X |
∑
x∈X
distp (H(x),Y(x)) → min; (4.13)
subject to : θ1 h1i (d) ≤ hi(d) ≤ θ2 h1i (d), d ∈ D, i = 1, ..., c. (4.14)
In the calculations below, we set θ1 = 0.01, θ2 = 2. The number of variables in this problem is
equal to |D| c. To solve this problem we apply the algorithm AGOP. We denote the solution found
by:
hGO(d) = (hGO1 (d), ..., h
GO
c (d)), d ∈ D. (4.15)
5 Evaluation Measures
In this section we describe two evaluations measures that will be used in numerical experiments.
First we aim to evaluate the accuracy of established drug-reaction relations by a given classifier;
that is, to evaluate the closeness of the two vectors H(x) (predicted reactions) and Y(x)
(observed reactions). For this aim, we will use the Average Precision measure considered in [15].
Note that, this measure is based on the ordering of weights in H(x), and it allows us to achieve
more complete evaluation in multi-label classification problems. In the second evaluation measure
we consider two sets of drugs for each patient: the drugs in interaction and the others. The aim
here is to evaluate the “responsibility (weight)” of drugs in interaction, compared with the others,
in the reactions observed for this patient. The second evaluation measure is based on distance
between H(x) and Y(x).
5.1 Average Precision
Let Y (x) = {l ∈ {1, . . . , c} : Yl(x) = 1} be the set of reactions that have been observed for the
patient x and H(x) = {H1(x), · · · ,Hc(x)} be potential reactions calculated for this patient. We
denote by T (x) the set of all ordered reactions τ = {i1, . . . , ic} satisfying the condition
Hi1(x) ≥ . . . ≥ Hic(x);
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where ik ∈ {1, . . . , c} and ik 6= im if k 6= m.
In the case, when the numbers Hi(x), i = 1, · · · , c, are different, there is just one order
satisfying this condition. But if there are reactions having the same weights then we can order
potential reactions in different ways; that is, in this case the set T (x) contains more than one
order.
Given order τ = {τ1, . . . , τc} ∈ T (x), we define the rank for each reaction l ∈ Y (x) as
rankτ (x; l) = k, where the number k satisfies τk = l. Then Precision is defined as:
Pτ (x) =
1
|Y (x)|
∑
l∈Y (x)
|{k ∈ Y (x) : rankτ (x; k) ≤ rankτ (x; l)}|
rankτ (x; l)
.
Here, we use the notation |S| for the cardinality of the set S. This measure has the following
meaning. For instance, if all observed reactions Y (x) have occurred on the top of ordering τ then
Pτ (x) = 1. Clearly the number Pτ (x) depends on order τ. We define
Pbest(x) = max
τ∈T (x)
Pτ (x) and Pworst(x) = min
τ∈T (x)
Pτ (x),
which are related to the “best” and “worst” ordering. Therefore, it is sensible to define the Precision
as the midpoint of these two versions: P (x) = (Pbest(x) + Pworst(x))/2.
Average Precision over all records X will be defined as:
Pav =
1
|X |
∑
x∈X
P (x). (5.16)
5.2 The evaluation of responsibility of drugs in interaction
Consider a particular patient x and let D(x) be the set of drugs used by this patient and Y(x) be
the set of observed reactions. The set D(x) consists of two parts: DI(x) - drugs under interaction
and DO(x) - the other drugs.
The method of evaluation is based on distance measure (4.3). Assume that for each drug d ∈ D
the vector of weights h(d) are calculated. Then, by formula 2.1, we can define potential reactions
HI(x) and HO(x), corresponding to the sets of drugs interacted - DI(x), and the other drugs -
DO(x), respectively:
HI(x) = H(DI(x)), HO(x) = H(DO(x)).
The method, used in this paper for the evaluation of responsibility of drugs in interaction, can
be identified as “all drugs interacted versus all the other drugs taken”. For this aim we consider
convex combinations of these two group of drugs and try to find the optimal combination which
provides the maximal closeness to the reactions observed. In other words we are looking for a
combination of interacted and non-interacted drugs which is optimal in the sense of distance (4.3).
Before considering convex combinations we need to be careful about the “comparability” of the
vectors HI(x) and HO(x) in the sense of scaling. For this reason, it is meaningful to consider
convex combinations of normalized (see (4.4)) vectors H¯I(x) and H¯O(x). Therefore we define
H¯(x, µ) = µ H¯I(x) + (1− µ) H¯O(x), 0 ≤ µ ≤ 1. (5.17)
Note that, ‖H¯I(x)‖ = ‖H¯O(x)‖ = ‖Y(x)‖ and, therefore, ‖H¯(x, µ)‖ = ‖Y(x)‖ for all µ ∈ [0, 1].
The number µ indicates the proportion of the drugs interacted and the other drugs in the
definition of potential reactions. Clearly, H¯(x, 1) = H¯I(x) and H¯(x, 0) = H¯O(x), which implies
dist(H¯(x, 1),Y(x)) = dist(HI(x),Y(x)),
dist(H¯(x, 0),Y(x)) = dist(HO(x),Y(x)).
It is important to note that, the combination of all drugs with equal weights; that is, the vector
HA(x) = H(D(x)) = HI(x)+HO(x) is also considered in (5.17). To confirm this, it is sufficient to
consider the case ‖HI(x)‖ > 0 and ‖HO(x)‖ > 0. In this case ‖HA(x)‖ = ‖HI(x)‖+‖HO(x)‖ > 0.
Then we take µ′ = ‖HI(x)‖/‖HA(x)‖ ∈ (0, 1) and get (see (4.4))
H¯(x, µ′) = µ′ ‖Y(x)‖‖HI(x)‖H
I(x) + (1− µ′) ‖Y(x)‖‖HO(x)‖H
O(x)
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=
‖Y(x)‖
‖HA(x)‖H
I(x) +
‖Y(x)‖
‖HA(x)‖H
O(x) = H¯A(x);
which implies
dist(H¯(x, µ′),Y(x)) = dist(H¯A(x),Y(x)) = dist(HA(x),Y(x)).
Consider the following minimization problem with respect to µ;
f(µ) .= dist (H¯(x, µ),Y(x)) =
c∑
i=1
(H¯i(x, µ)− Yi(x))2 → min; 0 ≤ µ ≤ 1. (5.18)
The optimal solution µ∗ to problem (5.18) gives an information about the responsibility of drugs
interacted. For instance, if µ∗ = 1 then we see that the drugs interacted provide the better
approximation to the observed reactions than if we involve the other drugs. We refer this situation
as 100 percent responsibility. Whereas, if µ∗ = 0 then the other drugs provide better approximation
to the observed reactions and we can conclude that in this case drugs interacted are defined
completely non-responsible. Therefore, the optimal value µ∗ can be considered as an evaluation
measure for the responsibility of drugs interacted.
From (4.5) we obtain the following:
Proposition 5.1 The optimal solution µ∗ to the problem (5.18) is optimal with respect to the
all distance measures distp, p = 0, 1, 2; that is, given vectors of weights h(d), d ∈ D(x), for all
p = 0, 1, 2 the following inequality holds:
distp(H¯(x, µ∗),Y(x)) ≤ distp(H¯(x, µ),Y(x)), for all µ ∈ [0, 1].
This proposition shows that, given patient x ∈ X and given vectors of weights h(d), the defi-
nition of responsibility of drugs interacted, as an optimal value µ∗, does not depend on choice of
distance functions dist and distp, p = 0, 1, 2.
It is clear that, problem (5.18) can have many optimal solutions µ∗; that is, different proportions
of interacted and other drugs can provide the same closeness to the observed reactions. In this
case we will define the responsibility of drugs interacted, as the maximal value among all optimal
solutions µ∗ :
µ∗(x) = max{µ∗ : µ∗ is an optimal solution to (5.18)}. (5.19)
The reason for such a definition can be explained; for instance, if µ∗ = 1 (only interacted drugs)
and µ∗ = 0 (only the other drugs) are the two different optimal solutions, giving the closest ap-
proximation to the observed reactions, then there would be no reason to doubt the responsibility
of drugs interacted.
Problem (5.18) can be easily solved. Let
A =
c∑
j=1
(zi ‖Y(x)‖ − z Yi(x))
(
zi ‖H¯O(x)‖ − z H¯Oi (x)
)
;
B =
c∑
j=1
(H¯Oi (x) ‖Y(x)‖ − ‖H¯O(x)‖Yi(x)) (zi ‖H¯O(x)‖ − z H¯Oi (x)) ;
where zi = H¯Ii (x)− H¯Oi (x), z = ‖H¯I(x)‖ − ‖H¯O(x)‖. Then, we find the derivative of the function
f(µ), defined by (5.18), in the following form:
f ′(µ) =
2
(zµ+ ‖H¯O(x)‖)4 (Aµ+B). (5.20)
From (5.20) we have
Proposition 5.2 The optimal solution µ∗(x) to the problem (5.18) can be found as follows.
1) Let A = 0. Then
µ∗(x) =
{
0 if B > 0;
1 otherwise.
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2) Let A > 0. Then
µ∗(x) =
{
0 if B > 0;
min{1, −B/A} otherwise.
3) Let A < 0. Then
µ∗(x) =
{
0 if f(0) < f(1);
1 otherwise.
Therefore, we have defined the responsibility of drugs interacted for a particular patient x.
Given set of patients X , Average Responsibility of drugs in interaction will be calculated as
Pint =
1
|X |
∑
x∈X
µ∗(x). (5.21)
The numbers P (x) and µ∗(x), in formulae 5.16 and 5.21, give some information about each
interaction case. For instance, if P (x) = 1 (that is, 100 percent) and µ∗(x) = 1 then we can
conclude that the potential reactions defined by the drugs in interaction provide 100 percent
correct prediction of reactions in both evaluation measures. Therefore, in this case, we can say
that the potential reactions could be used for reaction predictions in the case of interactions.
6 The results of numerical experiments
We will consider three versions of the algorithm A(p), corresponding to the distance functions
distp, p = 0, 1, 2, respectively. Each of these versions tends to minimize the average distance
calculated by its own distance measure.
In the calculations below we take as a test set records sequentially from each year, starting
from 1996 until 2001. For example, if records from 1999, having drug-drug interactions, are taken
as a test set, then all records from years 1972-1998, including also drug interaction cases, form a
training set. Training sets are used to determine drug-reaction relationships.
We define a new drug (in the test set) as a case when this drug either is a new drug which has
not occurred in the training set or has never been considered as a suspected drug in the training
set. It is possible that in a new (test) example all drugs taken are new. We call this case a new
event. This situation mainly relates to the fact that, new drugs are constantly appearing on the
market. Obviously, to make analysis for such examples does not make sense. Therefore, in the
calculations below, we will remove all new events from test sets.
As mentioned in Section 5, for the evaluation, we will use two measures: Average Responsibility
- Pint and Average Precision Pav.
For our analysis we consider the records having more than 3 drugs, where some of drugs were
reported as interacted (in the ADRAC data the value 2 was associated with these drugs) and the
others were reported as non-suspected (the value 0 was used in this case). To make the problem
of evaluation of drug-drug interactions meaningful, we need to consider the records for which both
parts are non-empty sets.
The results obtained are presented in Tables 5-9. Training sets are used for calculating of
weights for each drug. As in [11], the weights are calculated by using suspected drugs. Then the
evaluation of interaction of drugs is done only for test sets, because, in training sets, drugs in
interaction (as suspected drugs) are used for the calculation of weights. The number of cases in
the test sets are also presented in these tables.
In the last row of Tables 5-9, we present the average results obtained by all test sets in a
particular class of reactions. To have some idea about the accuracy achieved, let us consider
the results obtained by the algorithm A(2) for the Cardiovascular class of reactions. We have
Pint = 71.6 and Pav = 82.8. The first number means that, in the observed reactions, the “degree
of responsibility” of the drugs in interaction versus the all other drugs, is more than 70 percent
which is sufficiently high. The second number indicates high accuracy in the prediction of these
reactions in terms of text categorization measure Average Precision.
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Considering the all ADRAC database (Table 5) we see that the degree of responsibility of the
drugs in interaction versus the all other drugs, is sufficiently high for all versions A(p), p = 1, 2, 3,
being around 75 percent. The Average Precision of approximately 68 percent is also quite high
taking into account the large number of classes (that is, 18 classes). This emphasizes that, drug-
drug interaction cases could be successfully explained and predicted by the weights calculated for
each drug.
In fact the accuracy of this method could be much higher if we could calculate weights more
“correctly”. To show this, we did the following.
First we note that, the numbers Pint and Pav are the average values of µ∗(x) and P (x) calculated
for each patient x (see Section 5). Different versions A(p) provide different values µ∗(x) and P (x).
We take the corresponding maximal values obtained by different versions A(p), p = 1, 2, 3, and
then calculate the average responsibility and precision. The results obtained are presented in
the columns “max” in Tables 5-9. These results are much better than the results obtained by a
particular version of A(p).
For the class Body (Table 7) the the degree of responsibility of the drugs in interaction is around
60 percent, but the Average Precision is very high - 98.7. This means that drugs in interaction,
along with the drug-reaction representations, can be used to predict the reactions that occurred
with high accuracy.
The highest accuracy is obtained for the class Blood (Table 6), where both Average Responsi-
bility of drugs in interaction and Average Precision is sufficiently high.
For the class Neurological (Table 9) the results presented in the columns “max” are sufficiently
high in both evaluation measures. The results obtained by a particular version of the algorithm
A(p) are low compared to “max”. This indicates the necessity for future investigations for more
efficient methods to calculate drug-reaction representations.
Table 5: Evaluation of drug-drug interactions: All Data; that is 18 SOC
Test N Pint Pav
Year A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 44 82.1 81.9 86.1 92.2 71.7 76.8 74.9 80.8
1997 45 74.0 67.1 63.6 79.4 66.2 65.3 62.5 71.9
1998 71 68.4 68.9 71.0 75.4 63.6 64.5 63.5 70.7
1999 18 70.3 58.0 65.1 80.6 71.0 68.0 68.6 72.7
2000 11 87.2 93.7 85.5 96.3 62.9 57.3 54.7 71.1
2001 53 79.4 81.1 82.0 87.4 75.0 73.1 68.4 78.6
total 242 75.3 74.0 75.0 83.2 68.6 68.7 66.5 74.7
Table 6: Evaluation of drug-drug interactions: class Blood
Test N Pint Pav
Year A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 22 79.1 77.7 75.5 79.6 97.7 97.0 99.2 100
1997 14 81.8 81.8 89.4 89.4 96.4 96.4 96.4 96.4
1998 16 83.7 83.0 82.4 83.9 96.9 96.9 95.8 96.9
1999 6 66.7 50.0 50.0 66.7 88.9 88.9 91.7 91.7
2000 1 100 100 100 100 100 100 100 100
2001 14 86.9 83.5 84.5 87.0 96.4 92.9 91.7 96.4
total 73 81.4 78.8 79.7 83.0 96.3 95.4 95.9 97.3
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Table 7: Evaluation of drug-drug interactions: class Body
Test N Pint Pav
Year A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 8 59.3 50.0 50.3 61.3 94.8 94.8 94.8 94.8
1997 10 60.0 70.0 70.0 70.0 100 100 100 100
1998 9 55.6 55.6 67.2 67.2 98.1 98.1 98.1 98.1
1999 6 50.0 50.0 48.1 59.1 100 100 100 100
2000 2 50.0 50.0 50.0 50.0 100 100 100 100
2001 11 72.7 63.6 63.4 81.8 100 100 100 100
total 46 60.3 58.7 60.7 68.5 98.7 98.7 98.7 98.7
Table 8: Evaluation of drug-drug interactions: class Cardiovascular
Test N Pint Pav
Year A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 4 48.1 78.7 81.0 92.0 87.5 89.6 87.5 89.6
1997 13 79.8 80.4 68.7 83.5 79.5 79.5 84.0 84.6
1998 8 87.5 82.7 88.8 88.8 61.5 68.8 79.2 79.2
1999 2 33.3 33.3 33.3 33.3 58.3 58.3 39.2 58.3
2000 2 50.0 50.0 98.1 100 75.0 75.0 100 100
2001 14 63.7 59.7 68.1 78.8 87.7 84.8 86.3 91.3
total 43 67.9 68.8 71.6 80.6 78.4 79.0 82.8 85.7
Table 9: Evaluation of drug-drug interactions: class Neurological
Test N Pint Pav
Year A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 11 36.4 36.4 36.4 45.5 62.1 59.8 59.8 65.2
1997 15 56.6 64.8 49.4 68.2 78.9 81.1 77.8 85.6
1998 16 70.9 64.3 68.1 81.0 69.8 85.4 87.0 90.6
1999 5 80.0 78.3 68.8 88.8 80.0 90.0 83.3 90.0
2000 5 0.0 50.64 60.0 60.0 51.7 65.0 75.0 75.0
2001 24 77.5 71.7 57.9 81.7 79.5 81.2 83.0 88.5
total 76 61.1 62.7 56.1 72.6 73.0 78.5 78.9 84.2
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7 Conclusion
In this paper we have presented a new optimization approach to study drug-drug interactions.
Our focus was comprehensive, considering the fact that all drug-reaction relations was taken into
account. We chose to traverse down the reaction tree from all ADRAC called All Data level down
to the level of individual class of reactions: Blood, Body, Cardiovascular and Neurological. The
suggested method of representation for drug-reaction relations in the form of a vector of weights
is examined for the prediction of reactions in drug-drug interaction cases. The results obtained
have shown that the reactions that occurred in the cases of interaction of drugs, reported in the
ADRAC data, could be predicted by this method with sufficiently high accuracy.
At the end we note that, the approach of drug-reaction representations has been implemented
in software. This software can be used to solve the following two problems:
• given a set of drugs to predict the reactions that are most likely to occur; and
• given a set of drugs and a set of reactions occurred, to determine the drugs that are the most
likely cause these reactions.
This software has potential application in prescribing activities by GPs and also in pharmacy and
dispensing.
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